The BH3-only Proteins Puma and Noxa: Two Brothers in Arms

Apoptosis and Cancer Therapy: From Cutting-edge Science to Novel Therapeutic Concepts

Volumn 1, Issue , 2008, Pages 379-402

  Erlacher, Miriam ^a   Michalak, Ewa M ^b   Strasser, Andreas ^b   Villunger, Andreas ^a  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^b WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH   (Australia)

Author keywords

Heterozygosity; Lymphomas; Nervous system; Neuroblastomas; Tumor

Indexed keywords

EID: 84873251640     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9783527619665.ch13     Document Type: Chapter

References (142)

1. Lane, D. P. and Crawford, L. V. T antigen is bound to a host protein in SV40transformed cells. Nature 278:261-263, 1979.
2. Linzer, D. I., Maltzman, W. and Levine, A. J. The SV40 A gene product is required for the production of a 54,000 MW cellular tumor antigen. Virology 98:308-318, 1979.
3. Vogelstein, B., Lane, D. and Levine, A. J. Surfing the p53 network. Nature 408:307-310, 2000.
4. Vousden, K. H. and Lu, X. Live or let die: the cell's response to p53. Nat Rev Cancer 2:594-604, 2002.
5. Hollstein, M., Sidransky, D., Vogelstein, B. and Harris, C. C. p53 mutations in human cancers. Science 253:49-53, 1991.
6. Malkin, D. et al. Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science 250:1233-1238, 1990.
7. Srivastava, S., Zou, Z. Q., Pirollo, K., Blattner, W. and Chang, E. H. Germ-line transmission of a mutated p53 gene in a cancer-prone family with Li-Fraumeni syndrome. Nature 348:747-749, 1990.
8. Donehower, L. A. et al. Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumors. Nature 356:215-221, 1992.
9. Jacks, T. et al. Tumor spectrum analysis in p53 -mutant mice. Curr Biol 4:1-7, 1994.
10. Olive, K. P. et al. Mutant p53 gain of function in two mouse models of LiFraumeni syndrome. Cell 119:847-860, 2004.
11. Lang, G. A. et al. Gain of function of a p53 hot spot mutation in a mouse model of Li-Fraumeni syndrome. Cell 119:861-872, 2004.
12. Harvey, M., McArthur, M. J., Montgomery, C. A., Jr., Bradley, A. and Donehower, L. A. Genetic background alters the spectrum of tumors that develop in p53 -deficient mice. FASEB J 7:938-943, 1993.
13. Sah, V P. et al. A subset of p53 -deficient embryos exhibit exencephaly. Nat Genet 10:175-180, 1995.
14. Lane, D. P. Cancer. p53, guardian of the genome. Nature 358:15-16, 1992.
15. Prives, C. and Hall, P. A. The p53 pathway. J Pathol 187:112-126, 1999.
16. Appella, E. and Anderson, C. W Signaling to p53: breaking the posttranslational modification code. Pathol Biol (Paris) 48:227-245, 2000.
17. Kastan, M. B., Onyekwere, O., Sidransky, D., Vogelstein, B. and Craig, R. W. Participation of p53 protein in the cellular response to DNA damage. Cancer Res 51:6304-6311, 1991.
18. Kuerbitz, S. J., Plunkett, B. S., Walsh, W V and Kastan, M. B. Wild-type p53 is a cell cycle checkpoint determinant following irradiation. Proc Natl Acad Sci USA 89:7491-7495, 1992.
19. Funk, W. D., Pak, D. T., Karas, R. H., Wright, W. E. and Shay, J. W. A transcriptionally active DNA-binding site for human p53 protein complexes. Mol Cell Biol 12:2866-2871, 1992.
20. Kubbutat, M. H., Jones, S. N. and Vousden, K. H. Regulation of p53 stability by Mdm2. Nature 387:299-303, 1997.
21. Dornan, D. et al. The ubiquitin ligase COP1 is a critical negative regulator of p53. Nature 429:86-92, 2004.
22. Canman, C. E. et al. Activation of the ATM kinase by ionizing radiation and phosphorylation of p53. Science 281:1677-1679, 1998.
23. Shieh, S. Y., Ahn, J., Tamai, K., Taya, Y. and Prives, C. The human homologs of checkpoint kinases Chk1 and Cds1 (Chk2) phosphorylate p53 at multiple DNA damage-inducible sites. Genes Dev 14:289-300, 2000.
24. Friend, S. p53: a glimpse at the puppet behind the shadow play. Science 265:334-335, 1994.
25. Greenblatt, M. S., Bennett, W. P., Hollstein, M. and Harris, C. C. Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res 54:4855-4878, 1994.
26. El Deiry, W S., Kern, S. E., Pietenpol, J. A., Kinzler, K. W. and Vogelstein, B. Definition of a consensus binding site for p53. Nat Genet 1:45-49, 1992.
27. Zhang, Y., Xiong, Y and Yarbrough, W G. ARF promotes MDM2 degradation and stabilizes p53: ARF-INK4a locus deletion impairs both the Rb and p53 tumor suppression pathways. Cell 92:725-734, 1998.
28. Kamijo, T. et al. Functional and physical interactions of the ARF tumor suppressor with p53 and Mdm2. Proc Natl Acad Sci USA 95:8292-8297, 1998.
29. Zindy, F. et al. Myc signaling via the ARF tumor suppressor regulates p53 -dependent apoptosis and immortalization. Genes Dev 12:2424-2433, 1998.
30. El Deiry, W. S. et al. WAF1, a potential mediator of p53 tumor suppression. Cell 75:817-825, 1993.
31. Hermeking, H. et al. 14-3-3 sigma is a p53 -regulated inhibitor of G2/M progression. Mol Cell 1:3-11, 1997.
32. Kastan, M. B. et al. A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia-telangiectasia. Cell 71:587-597, 1992.
33. 1 cyclin-dependent kinases. Cell 75:805-816, 1993.
34. Gottlieb, T. M. and Oren, M. p53 in growth control and neoplasia. Biochim Biophys Acta 1287:77-102, 1996.
35. Brugarolas, J. et al. Radiation-induced cell cycle arrest compromised by p21 deficiency. Nature 377:552-557, 1995.
36. Wang, X. W. et al. GADD45 induction of a G2/M cell cycle checkpoint. Proc Natl Acad Sci USA 96:3706-3711, 1999.
37. Chan, T. A., Hermeking, H., Lengauer, C., Kinzler, K. W. and Vogelstein, B. 14-33Sigma is required to prevent mitotic catastrophe after DNA damage. Nature 401:616-620, 1999.
38. Zhan, Q. et al. Association with Cdc2 and inhibition of Cdc2/Cyclin B1 kinase activity by the p53 -regulated protein Gadd45. Oncogene 18:2892-2900, 1999.
39. 2-M arrest associates with altered subcellular distribution of cyclin B1 and is independent of p38 kinase activity. Oncogene 21:8696-8704, 2002.
40. Buckbinder, L. et al. Induction of the growth inhibitor IGF-binding protein 3 by p53. Nature 377:646-649, 1995.
41. Neuberg, M., Buckbinder, L., Seizinger, B. and Kley, N. The p53/IGF-1 receptor axis in the regulation of programmed cell death. Endocrine 7:107-109, 1997.
42. Stambolic, V. et al. Regulation of PTEN transcription by p53. Mol Cell 8:317-325, 2001.
43. Di Cristofano, A. and Pandolfi, P. P. The multiple roles of PTEN in tumor suppression. Cell 100:387-390, 2000.
44. Di Cristofano, A., Pesce, B., CordonCardo, C. and Pandolfi, P. P. Pten is essential for embryonic development and tumor suppression. Nat Genet 19:348-355, 1998.
45. Suzuki, A. et al. High cancer susceptibility and embryonic lethality associated with mutation of the PTEN tumor suppressor gene in mice. Curr Biol 8:1169-1178, 1998.
46. Stambolic, V. et al. Negative regulation of PKB/Akt-dependent cell survival by the tumor suppressor PTEN. Cell 95:29-39, 1998.
47. Yonish-Rouach, E. et al. Wild-type p53 induces apoptosis of myeloid leukaemic cells that is inhibited by interleukin6. Nature 352:345-347, 1991.
48. Lowe, S. W, Schmitt, E. M., Smith, S. W, Osborne, B. A. and Jacks, T. p53 is required for radiation-induced apoptosis in mouse thymocytes. Nature 362:847-849, 1993.
49. Clarke, A. R. et al. Thymocyte apoptosis induced by p53 -dependent and independent pathways. Nature 362:849-852, 1993.
50. Strasser, A., Harris, A. W., Jacks, T. and Cory, S. DNA damage can induce apoptosis in proliferating lymphoid cells via p53 -independent mechanisms inhibitable by Bcl-2. Cell 79:329-339, 1994.
51. Cip1 Cdk inhibitor influences the outcome of the p53 response to DNA damage. Nature 419:729-734, 2002.
52. Kaeser, M. D. and Iggo, R. D. Chromatin immunoprecipitation analysis fails to support the latency model for regulation of p53 DNA binding activity in vivo. Proc Natl Acad Sci USA 99:95-100, 2002.
53. Giampieri, S., Garcia-Escudero, R., Green, J. and Storey, A. Human papillomavirus type 77 E6 protein selectively inhibits p53 -dependent transcription of proapoptotic genes following UV-B irradiation. Oncogene 23:5864-5870, 2004.
54. Vaux, D. L., Cory, S. and Adams, J. M. Bcl-2 gene promotes haemopoietic cell survival and cooperates with c-myc to immortalize pre-B cells. Nature 335:440-442, 1988.
55. Strasser, A., Harris, A. W, Bath, M. L. and Cory, S. Novel primitive lymphoid tumors induced in transgenic mice by cooperation between myc and bcl-2. Nature 348:331-333, 1990.
56. Hanahan, D. and Weinberg, R. A. The hallmarks of cancer. Cell 100:57-70, 2000.
57. Bissonnette, N., Wasylyk, B. and Hunting, D. J. The apoptotic and transcriptional transactivation activities of p53 can be dissociated. Biochem Cell Biol 75:351-358, 1997.
58. Haupt, Y., Rowan, S., Shaulian, E., Vousden, K. H. and Oren, M. Induction of apoptosis in HeLa cells by trans-activation-deficient p53. Genes Dev 9:2170-2183, 1995.
59. Chipuk, J. E., Maurer, U., Green, D. R. and Schuler, M. Pharmacologic activation of p53 elicits Bax-dependent apoptosis in the absence of transcription. Cancer Cell 4:371-381, 2003.
60. Chipuk, J. E. et al. Direct activation of Bax by p53 mediates mitochondrial membrane permeabilization and apoptosis. Science 303:1010-1014, 2004.
61. Mihara, M. et al. p53 has a direct apoptogenic role at the mitochondria. Mol Cell 11:577-590, 2003.
62. Erster, S., Mihara, M., Kim, R. H., Petrenko, O. and Moll, U. M. In vivo mitochondrial p53 translocation triggers a rapid first wave of cell death in response to DNA damage that can precede p53 target gene activation. Mol Cell Biol 24:6728-6741, 2004.
63. Yamaguchi, H., Chen, J., Bhalla, K. and Wang, H. G. Regulation of Bax activation and apoptotic response to microtubuledamaging agents by p53 transcriptiondependent and-independent pathways. J Biol Chem 279:39431-39437, 2004.
64. Leu, J. I., Dumont, P., Hafey, M., Murphy, M. E. and George, D. L. Mitochondrial p53 activates Bak and causes disruption of a Bak-Mcl1 complex. Nat Cell Biol 6:443-450, 2004.
65. Ashkenazi, A. and Dixit, V. M. Death receptors: signaling and modulation. Science 281:1305-1308, 1998.
66. Owen-Schaub, L. B. et al. Wild-type human p53 and a temperature-sensitive mutant induce Fas/APO-1 expression. Mol Cell Biol 15:3032-3040, 1995.
67. Muller, M. et al. p53 activates the CD95 (APO-1/Fas) gene in response to DNA damage by anticancer drugs. J Exp Med 188:2033-2045, 1998.
68. Wu, G. S. et al. KILLER/DR5 is a DNA damage-inducible p53 -regulated death receptor gene. Nat Genet 17:141-143, 1997.
69. Newton, K., Harris, A. W., Bath, M. L., Smith, K. G. and Strasser, A. A dominant interfering mutant of FADD/MORT1 enhances deletion of autoreactive thymocytes and inhibits proliferation of mature T lymphocytes. EMBO J 17:706-718, 1998.
70. Newton, K. and Strasser, A. Ionizing radiation and chemotherapeutic drugs induce apoptosis in lymphocytes in the absence of Fas or FADD/MORT1 signaling. Implications for cancer therapy. J Exp Med 191:195-200, 2000.
71. O'Connor, L., Harris, A. W. and Strasser, A. CD95 (Fas/APO-1) and p53 signal apoptosis independently in diverse cell types. Cancer Res 60:1217-1220, 2000.
72. Bennett, M. et al. Cell surface trafficking of Fas: a rapid mechanism of p53 -mediated apoptosis. Science 282:290-293, 1998.
73. Kuang, A. A., Diehl, G. E., Zhang, J. and Winoto, A. FADD is required for DR4and DR5 -mediated apoptosis: lack of trail-induced apoptosis in FADD-deficient mouse embryonic fibroblasts. J Biol Chem 275:25065-25068, 2000.
74. Corazza, N., Brumatti, G., Jakob, S., Villunger, A. and Brunner, T. TRAIL and thymocyte apoptosis: not so deadly? Cell Death Differ 11 (Suppl 2):S213-S215, 2004.
75. Yeh, W. C. et al. FADD: essential for embryo development and signaling from some, but not all, inducers of apoptosis. Science 279:1954-1958, 1998.
76. Varfolomeev, E. E. et al. Targeted disruption of the mouse Caspase 8 gene ablates cell death induction by the TNF receptors, Fas/Apo1, and DR3 and is lethal prenatally. Immunity 9:267-276, 1998.
77. Strasser, A., O'Connor, L. and Dixit, V. M. Apoptosis signaling. Annu Rev Biochem 69:217-245, 2000.
78. Robles, A. I., Bemmels, N. A., Foraker, A. B. and Harris, C. C. APAF-1 is a transcriptional target of p53 in DNA damage-induced apoptosis. Cancer Res 61:6660-6664, 2001.
79. Fortin, A. et al. APAF1 is a key transcriptional target for p53 in the regulation of neuronal cell death. J Cell Biol 155:207-216, 2001.
80. Moroni, M. C. et al. Apaf-1 is a transcriptional target for E2F and p53. Nat Coll Biol 3:552-558, 2001.
81. Huang, D. C. and Strasser, A. BH3-Only proteins-essential initiators of apoptotic cell death. Cell 103:839-842, 2000.
82. Puthalakath, H. and Strasser, A. Keeping killers on a tight leash: transcriptional and post-translational control of the proapoptotic activity of BH3 -only proteins. Cell Death Differ 9:505-512, 2002.
83. Cory, S. and Adams, J. M. The Bcl2 family: regulators of the cellular life-ordeath switch. Nat Rev Cancer 2:647-656, 2002.
84. Letai, A. et al. Distinct BH3 domains either sensitize or activate mitochondrial apoptosis, serving as prototype cancer therapeutics. Cancer Cell 2:183-192, 2002.
85. Chen, L. et al. Differential targeting of prosurvival Bcl-2 proteins by their BH3 -only ligands allows complementary apoptotic function. Mol Cell 17:393-403, 2005.
86. Lindsten, T et al. The combined functions of proapoptotic Bcl-2 family members bak and bax are essential for normal development of multiple tissues. Mol Cell 6:1389-1399, 2000.
87. Zong, W. X., Lindsten, T., Ross, A. J., MacGregor, G. R. and Thompson, C. B. BH3 -only proteins that bind pro-survival Bcl-2 family members fail to induce apoptosis in the absence of Bax and Bak. Genes Dev 15:1481-1486, 2001.
88. Miyashita, T. and Reed, J. C. Tumor suppressor p53 is a direct transcriptional activator of the human bax gene. Cell 80:293-299, 1995.
89. Sax, J. K. et al. BID regulation by p53 contributes to chemosensitivity. Nat Cell Biol 4:842-849, 2002.
90. Knudson, C. M., Tung, K. S., Tourtellotte, W. G., Brown, G. A. and Korsmeyer, S. J. Bax-deficient mice with lymphoid hyperplasia and male germ cell death. Science 270:96-99, 1995.
91. McCurrach, M. E., Connor, T. M., Knudson, C. M., Korsmeyer, S. J. and Lowe, S. W. bax-deficiency promotes drug resistance and oncogenic transformation by attenuating p53 -dependent apoptosis. Proc Natl Acad Sci USA 94:2345-2349, 1997.
92. Brady, H. J., Salomons, G. S., Bobeldijk, R. C. and Berns, A. J. T cells from baxalpha transgenic mice show accelerated apoptosis in response to stimuli but do not show restored DNA damage-induced cell death in the absence of p53. EMBO J 15:1221-1230, 1996.
93. Melino, G. et al. p73 Induces apoptosis via PUMA transactivation and Bax mitochondrial translocation. J Biol Chem 279:8076-8083, 2004.
94. Yin, X. M. et al. Bid-deficient mice are resistant to Fas-induced hepatocellular apoptosis. Nature 400:886-891, 1999.
95. Yu, J., Zhang, L., Hwang, P. M., Kinzler, K. W. and Vogelstein, B. PUMA induces the rapid apoptosis of colorectal cancer cells. Mol Cell 7:673-682, 2001.
96. Nakano, K. and Vousden, K. H. PUMA, a novel proapoptotic gene, is induced by p53. Mol Cell 7:683-694, 2001.
97. Han, J. et al. Expression of bbc3, a proapoptotic BH3 -only gene, is regulated by diverse cell death and survival signals. Proc Natl Acad Sci USA 98:11318-11323, 2001.
98. Fei, P., Bernhard, E. J. and El Deiry, W. S. Tissue-specific induction of p53 targets in vivo. Cancer Res 62:7316-7327, 2002.
99. Brunelle, J. K. et al. c-Myc sensitization to oxygen deprivation-induced cell death is dependent on Bax/Bak, but is independent of p53 and hypoxia-inducible factor-1. J Biol Chem 279:4305-4312, 2004.
100. Ashur-Fabian, O. et al. Evolution of p53 in hypoxia-stressed Spalax mimics human tumor mutation. Proc Natl Acad Sci USA 101:12236-12241, 2004.
101. Nelson, D. A. et al. Hypoxia and defective apoptosis drive genomic instability and tumorigenesis. Genes Dev 18:2095-2107, 2004.
102. Eldering, E. et al. Expression profiling via novel multiplex assay allows rapid assessment of gene regulation in defined signalling pathways. Nucleic Acids Res 31:e153, 2003.
103. Gu, J. et al. Induction of p53 -regulated genes in lung cancer cells: implications of the mechanism for adenoviral p53mediated apoptosis. Oncogene 23:1300-1307, 2004.
104. Flores, E. R. et al. p63 and p73 are required for p53 -dependent apoptosis in response to DNA damage. Nature 416:560-564, 2002.
105. Reimertz, C., Kogel, D., Rami, A., Chittenden, T. and Prehn, J. H. Gene expression during ER stress-induced apoptosis in neurons: induction of the BH3only protein Bbc3/PUMA and activation of the mitochondrial apoptosis pathway. J Cell Biol 162:587-597, 2003.
106. Yu, J., Wang, Z., Kinzler, K. W., Vogelstein, B. and Zhang, L. PUMA mediates the apoptotic response to p53 in colorectal cancer cells. Proc Natl Acad Sci USA 100:1931-1936, 2003.
107. Liu, F. T., Newland, A. C. and Jia, L. Bax conformational change is a crucial step for PUMA-mediated apoptosis in human leukemia. Biochem Biophys Res Commun 310:956-962, 2003.
108. Cartron, P. F. et al. The first alpha helix of Bax plays a necessary role in its ligandinduced activation by the BH3 -only proteins Bid and PUMA. Mol Cell 16:807-818, 2004.
109. Oda, E. et al. Noxa, a BH3 -only member of the Bcl-2 family and candidate mediator of p53 -induced apoptosis. Science 288:1053-1058, 2000.
110. Coultas, L., Huang, D. C., Adams, J. M. and Strasser, A. Proapoptotic BH3 -only Bcl2 family members in vertebrate model organisms suitable for genetic experimentation. Cell Death Differ 9:1163-1166, 2002.
111. Hijikata, M., Kato, N., Sato, T., Kagami, Y. and Shimotohno, K. Molecular cloning and characterization of a cDNA for a novel phorbol-12 -myristate-13 -acetate-responsive gene that is highly expressed in an adult T-cell leukemia cell line. J Virol 64:4632-4639, 1990.
112. Merritt, A. J., Allen, T. D., Potten, C. S. and Hickman, J. A. Apoptosis in small intestinal epithelial from p53 -null mice: evidence for a delayed, p53 -independent G2/M-associated cell death after gammairradiation. Oncogene 14:2759-2766, 1997.
113. Kim, J. Y., Ahn, H. J., Ryu, J. H., Suk, K. and Park, J. H. BH3 -only protein Noxa is a mediator of hypoxic cell death induced by hypoxia-inducible factor 1alpha. J Exp Med 199:113-124, 2004.
114. Flinterman, M. et al. E1A activates transcription of p73 and Noxa to induce apoptosis. J Biol Chem 280:5945-5959, 2005.
115. Schuler, M. et al. p53 triggers apoptosis in oncogene-expressing fibroblasts by the induction of Noxa and mitochondrial Bax translocation. Cell Death Differ 10:451-460, 2003.
116. Shibue, T. et al. Integral role of Noxa in p53 -mediated apoptotic response. Genes Dev 17:2233-2238, 2003.
117. Seo, Y. W. et al. The molecular mechanism of Noxa-induced mitochondrial dysfunction in p53 -mediated cell death. J Biol Chem 278:48292-48299, 2003.
118. Villunger, A. et al. p53 -and drug-induced apoptotic responses mediated by BH3 -only proteins puma and noxa. Science 302:1036-1038, 2003.
119. Jeffers, J. R. et al. Puma is an essential mediator of p53 -dependent and-independent apoptotic pathways. Cancer Cell 4:321-328, 2003.
120. Nijhawan, D. et al. Elimination of Mcl-1 is required for the initiation of apoptosis following ultraviolet irradiation. Genes Dev 17:1475-1486, 2003.
121. Erlacher, M. et al. The BH3 -only proteins Puma/bbc3 and Bim are rate-limiting for g-radiationand glucocorticoid-induced apoptosis of lymphoid cells in vivo. Submitted, 2005.
122. Bouillet, P. et al. Proapoptotic Bcl-2 relative Bim required for certain apoptotic responses, leukocyte homeostasis, and to preclude autoimmunity. Science 286:1735-1738, 1999.
123. Waf1/Cip1-deficient mice. Cancer Res 61:6234-6238, 2001.
124. Schmitt, C. A. et al. Dissecting p53 tumor suppressor functions in vivo. Cancer Cell 1:289-298, 2002.
125. Scott, C. L. et al. Apaf-1 and caspase-9 do not act as tumor suppressors in myc-induced lymphomagenesis or mouse embryo fibroblast transformation. J Cell Biol 164:89-96, 2004.
126. Strasser, A., Harris, A. W. and Cory, S. E mu-bcl-2 transgene facilitates spontaneous transformation of early pre-B and immunoglobulin-secreting cells but not T cells. Oncogene 8:1-9, 1993.
127. Liu, G. et al. Chromosome stability, in the absence of apoptosis, is critical for suppression of tumorigenesis in Trp53 mutant mice. Nat Genet 36:63-68, 2004.
128. L. Mol Cell Biol 23:7256-7270, 2003.
129. Adams, J. M. et al. The c-myc oncogene driven by immunoglobulin enhancers induces lymphoid malignancy in transgenic mice. Nature 318:533-538, 1985.
130. Blyth, K. et al. Synergy between a human c-myc transgene and p53 null genotype in murine thymic lymphomas: contrasting effects of homozygous and heterozygous p53 loss. Oncogene 10:1717-1723, 1995.
131. Yu, D. and Thomas-Tikhonenko, A. A non-transgenic mouse model for B-cell lymphoma: in vivo infection of p53 -null bone marrow progenitors by a Myc retrovirus is sufficient for tumorigenesis. Oncogene 21:1922-1927, 2002.
132. Eischen, C. M., Weber, J. D., Roussel, M. F., Sherr, C. J. and Cleveland, J. L. Disruption of the ARF-Mdm2 -p53 tumor suppressor pathway in Myc-induced lymphomagenesis. Genes Dev 13:2658-2669, 1999.
133. Hemann, M. T. et al. Suppression of tumorigenesis by the p53 target PUMA. Proc Natl Acad Sci USA 101:9333-9338, 2004.
134. Tan, T. T. et al. Key roles of BIM-driven apoptosis in epithelial tumors and rational chemotherapy. Cancer Cell 7:227-238, 2005.
135. Eferl, R. et al. Liver tumor development. c-Jun antagonizes the proapoptotic activity of p53. Cell 112:181-192, 2003.
136. Shimazaki, C., Inaba, T. and Nakagawa, M. B-cell lymphoma-associated hemo-phagocytic syndrome. Leuk Lymphoma 38:121-130, 2000.
137. Yong, W. H. et al. Cloning of a highly conserved human protein serine-threonine phosphatase gene from the glioma candidate region on chromosome 19q13.3. Genomics 29:533-536, 1995.
138. Mora, J., Cheung, N. K., Chen, L., Qin, J. and Gerald, W. Loss of heterozygosity at 19q13.3 is associated with locally aggressive neuroblastoma. Clin Cancer Res 7:1358-1361, 2001.
139. Hoque, M. O. et al. PUMA in head and neck cancer. Cancer Lett 199:75-81, 2003.
140. Jansson, A., Arbman, G. and Sun, X. F. mRNA and protein expression of PUMA in sporadic colorectal cancer. Oncol Rep 12:1245-1249, 2004.
141. Karst, A. M., Dai, D. L., Martinka, M. and Li, G. PUMA expression is significantly reduced in human cutaneous melanomas. Oncogene 24:1111-1116, 2005.
142. Lee, S. H. et al. Mutational analysis of Noxa gene in human cancers. APMIS 111:599-604, 2003.